Mark R Herbert

USPTO Granted Patents = 13 (Patent Applications = 4)

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 26(Granted Patents)

Location History:

Ramona, CA (US) (2017)
San Diego, CA (US) (2010 - 2024)

Company Filing History:

9 out of 34

Aragon Pharmaceuticals, Inc.

patents

7 out of 512

Sloan-kettering Institute for Cancer Research

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12018008 - Crystalline forms of an androgen receptor modulator (2024-06-25),

2. 10934271 - Crystalline forms of an androgen receptor modulator (2021-03-02),

3. 10766875 - Crystalline forms of an androgen receptor modulator (2020-09-08),

4. 10556882 - Crystalline forms of an androgen receptor modulator (2020-02-11),

5. 10526310 - Crystalline forms of an androgen receptor modulator (2020-01-07),

6. 10308630 - Crystalline forms of an androgen receptor modulator (2019-06-04),

7. 9994545 - Crystalline forms of an androgen receptor modulator (2018-06-12),

8. 9868704 - Estrogen receptor modulators and uses thereof (2018-01-16),

9. 9783503 - Crystalline forms of an estrogen receptor modulator (2017-10-10),

10. 9481663 - Crystalline forms of an androgen receptor modulator (2016-11-01),

11. 9399646 - Estrogen receptor modulators and uses thereof (2016-07-26),

12. 9340524 - Androgen receptor modulator and uses thereof (2016-05-17),

13. 7825256 - Inducible nitric oxide synthase dimerization inhibitors (2010-11-02),

Title: The Innovative Contributions of Mark R. Herbert: A Patent Overview

Introduction: Mark R. Herbert, an accomplished inventor based in San Diego, CA, holds an impressive portfolio of 13 patents. His work primarily focuses on advancements in pharmaceutical compositions aimed at treating disease conditions linked to androgen receptor activity. Through his dedication to research and innovation, he has made significant contributions to the field of medicinal chemistry.

Latest Patents: Among Mark R. Herbert's recent patents are crystalline forms of an androgen receptor modulator, specifically described by the chemical compound 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. This patent includes detailed descriptions of both amorphous and crystalline forms of the modulator, alongside pharmaceutical compositions suitable for administration to mammals. The innovations outlined also encompass methods of utilizing the modulator, either independently or in conjunction with other compounds, to treat various diseases or conditions associated with androgen receptor activity.

Career Highlights: Throughout his career, Mark R. Herbert has worked with notable organizations, including Aragon Pharmaceuticals, Inc. and the Sloan-Kettering Institute for Cancer Research. His position in these institutions emphasizes his commitment to advancing cancer research and therapeutic development.

Collaborations: Mark has had the privilege of collaborating with talented colleagues, such as Nicholas D. Smith and Ouathek Ouerfelli. These collaborations have enriched his research and led to significant advancements in the field.

Conclusion: Mark R. Herbert's innovative patents and contributions to pharmaceutical science highlight his status as a leading inventor in the area of androgen receptor modulators. His work not only demonstrates his expertise but also reflects the impact of collaborative research in the medical field. With a focus on improving treatment options, Mark continues to be a pioneering force in the realm of medicinal innovations.

This text is generated by artificial intelligence and may not be accurate.